Genzyme Corporation (NASDAQ: GENZ) today reported four-year follow-up data from its completed Phase 2 multiple sclerosis (MS) trial showing an ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE